Interfering with Hedgehog Pathway: New Avenues for Targeted Therapy in Rhabdomyosarcoma

Author(s): Gabriele Manzella, Beat W. Schäfer

Journal Name: Current Drug Targets

Volume 17 , Issue 11 , 2016

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Rhabdomyosarcoma (RMS) is the most frequent pediatric soft-tissue tumor accounting for about 7% of childhood malignancies. Multimodal therapy is the standard treatment for individuals with RMS but generally fails to cure high-risk group patients and can result in long-term side effects. Therefore, understanding the mechanisms driving RMS might help to find new candidate targets for more specific and effective therapeutic modalities. One of the molecular machineries which is often deregulated in cancer and specifically involved in tumorigenesis of RMS, is Hedgehog (Hh) signaling. There is increasing evidence that targeting this developmental pathway may hold promise in future treatment strategies for RMS. In this review, we discuss the contribution of the Hh pathway in RMS, the challenges of inhibiting this embryonic signaling in children with an update on recent preclinical data and ongoing clinical trials.

Keywords: Pediatric cancers, rhabdomyosarcoma, developmental pathways, hedgehog signaling, mouse models, targeted therapy.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 05 May, 2015
Page: [1228 - 1234]
Pages: 7
DOI: 10.2174/1389450116666150505122604
Price: $65

Article Metrics

PDF: 48
PRC: 1